Opinion on  Maxygen Inc. (MAXY)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
Maxygen Inc.

Maxygen, Inc., a biotechnology company, engages in the discovery, development, and commercialization of protein pharmaceuticals for treatment of disease and serious medical conditions in the United States. The company’s product candidates comprises MAXY-G34, a granulocyte colony stimulating factor that is in Phase IIa clinical trial for the treatment of neutropenia; MAXY-VII, a factor VIIa product that is in pre-clinical stage for the treatment of hemophilia and acute bleeding conditions; and MAXY-4, a CTLA-4-Ig product for the treatment of rheumatoid arthritis and other immune or autoimmune diseases. It has a strategic alliance with Roche Holdings, Ltd. for the development and commercialization of Maxygen's portfolio of next-generation interferon alpha and beta variants for a range of indications. The company was founded in 1996 and is headquartered in Redwood City, California.

 I picked MAXY at $4.48 before the July 4th holiday, its now at $4.91. I expect much more than this out of our Stock Picks. MAXY may just need a little more time.

It's now July 18th and MAXY is just below its 50-day moving average of $4.95. I have called several breakouts, we believe MAXY will be another.

With the Bayer deal, MAXY will soon be trading significantly under its cash value. MAXY has quietly moved higher the last three days. I don't believe MAXY will be quiet much longer.

MAXY's float is about 10% short, I could see a short squeeze happen in the next few days! MAXY really should be trading much higher!